Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...

Real-time index price for TSX Communication Services Capped Index (TTTS), along with buy or sell indicators, analysis, charts ...

Eli Lilly (LLY) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients. The ...

Short interest in Organovo Holdings Inc (NASDAQ:ONVO) decreased during the last reporting period, falling from 78.04K to 71.89K. This put 0.48% of the company's publicly available shares short.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares ...

China needs to tackle its steel glut by cutting 15% of capacity this year, if mills are to meet their 2025 climate goals and ...

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday. The Dow traded up 0.46% to 43,661.51 while the NASDAQ fell 1.07% to 19,080.23. The ...